U.S. Stem Cell, Inc. — key financial figures for fiscal year 2022 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2022)

$82.0K

Net Income/Loss (FY2022)

-$2.9M

Total Assets (FY2022)

$68.0K

Total Equity (FY2022)

-$14.7M

Cash Flows from Operating Activities (FY2022)

-$304.9K

Source: U.S. Stem Cell, Inc. 10-K filing (FY2022). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.